Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing-A Molecular Meta-Analysis

• Published in: Pharmaceutics Vol. 14; no. 1; p. 44
• Main Authors: Zouboulis, Viktor A, Zouboulis, Konstantin C, Zouboulis, Christos C
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.12.2021; MDPI
• Subjects: Acne; acne inversa; Atherosclerosis; Bibliographic records; Bioinformatics; biomarker; Biomarkers; comorbid disorder; Cytokines; Diabetes; Gene expression; hidradenitis suppurativa; Inflammatory bowel disease; Laboratories; Meta-analysis; Ontology; Proteins; proteome; Public domain; Signal transduction; Skin; Systematic Review; transcriptome; Tumor necrosis factor-TNF; New York; United States > US; acne inversa; drug repurposing; transcriptome; signaling pathway; comorbid disorder; hidradenitis suppurativa; biomarker; druggable gene; proteome
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14010044

Chronic inflammation and dysregulated epithelial differentiation, especially of hair follicle keratinocytes, have been suggested as the major pathogenetic pathways of hidradenitis suppurativa/acne inversa (HS). On the other hand, obesity and metabolic syndrome have additionally been considered as an important risk factor. With adalimumab, a drug has already been approved and numerous other compounds are in advanced-stage clinical studies. A systematic review was conducted to detect and corroborate HS pathogenetic mechanisms at the molecular level and identify HS molecular markers. The obtained data were used to confirm studied and off-label administered drugs and to identify additional compounds for drug repurposing. A robust, strongly associated group of HS biomarkers was detected. The triad of HS pathogenesis, namely upregulated inflammation, altered epithelial differentiation and dysregulated metabolism/hormone signaling was confirmed, the molecular association of HS with certain comorbid disorders, such as inflammatory bowel disease, arthritis, type I diabetes mellitus and lipids/atherosclerosis/adipogenesis was verified and common biomarkers were identified. The molecular suitability of compounds in clinical studies was confirmed and 31 potential HS repurposing drugs, among them 10 drugs already launched for other disorders, were detected. This systematic review provides evidence for the importance of molecular studies to advance the knowledge regarding pathogenesis, future treatment and biomarker-supported clinical course follow-up in HS.